Tag Archives: csl behring

November, 2017

August, 2017

July, 2017

June, 2017

March, 2017

February, 2017

January, 2017

August, 2016

July, 2016

March, 2016

  • 7 March

    CSL’s Idelvion Approved for Treatment of Hemophilia B

    KING OF PRUSSIA, Pa. — 04 March 2016 In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00 IDELVION, CSL Behring’s long-acting recombinant albumin fusion protein, delivers on the company’s promise to develop and …